2025
Randomized phase 2 study to assess the role of single-agent nivolumab to maintain remission in acute myeloid leukemia
Pyzer A, Dillon L, Sharon E, Karrison T, Zha Y, Fulton N, Gui G, Andrew G, Streicher H, Sweet K, Yaghmour G, Liu J, Jonas B, Schimmer A, Grant S, Zeidan A, Hildebrandt G, Lowrey C, Mattison R, Palmisiano N, Salhotra A, Tzachanis D, Baer M, Lin T, Patel P, Chen H, Stadler W, Odenike O, Larson R, Gajewski T, Hourigan C, Stock W, Liu H. Randomized phase 2 study to assess the role of single-agent nivolumab to maintain remission in acute myeloid leukemia. Blood Advances 2025, 9: 2144-2152. PMID: 39928953, PMCID: PMC12051614, DOI: 10.1182/bloodadvances.2024015176.Peer-Reviewed Original ResearchRandomized phase II studyProgression-free survivalPhase II studyNivolumab armAdverse eventsObservation armOverall survivalII studyMedian duration of follow-upProgression-free survival curvesDuration of follow-upEfficacy of nivolumabIncomplete hematologic recoverySingle-agent nivolumabEvaluation of adverse eventsAcute myeloid leukemiaIncreased AEsAML chemotherapyMedian OSNivolumab administrationNivolumab maintenanceHematologic recoveryDisease relapseOpen-labelMedian duration
2023
Indirect treatment comparison of first-line CDK4/6-inhibitors in post-menopausal patients with HR+/HER2- metastatic breast cancer.
Zhao J, Fong K, Chan Y, Tey J, Dawood S, Lee S, Finn R, Sundar R, Lim J. Indirect treatment comparison of first-line CDK4/6-inhibitors in post-menopausal patients with HR+/HER2- metastatic breast cancer. Journal Of Clinical Oncology 2023, 41: 1071-1071. DOI: 10.1200/jco.2023.41.16_suppl.1071.Peer-Reviewed Original ResearchProgression-free survivalPost-menopausal patientsIndirect treatment comparisonCDK4/6 inhibitorsPALOMA-2MONARCH 3OS differenceOverall survivalAromatase inhibitorsPatient-level time-to-event dataEndpoint of progression-free survivalFirst-line aromatase inhibitorsProgression-free survival differenceHR+/HER2- metastatic breast cancerHormone receptor positive (HR+)/human epidermal growth factor receptor 2Epidermal growth factor receptor 2Progression-free survival curvesPhase III randomized controlled trialsCDK4/6 inhibitor palbociclibMetastatic breast cancerPhase III studyKaplan-Meier OSCox proportional hazards modelsProportional hazards modelTreatment comparisons
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply